{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T01:39:17Z","timestamp":1773970757291,"version":"3.50.1"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Study Design<\/jats:title><jats:p>A Systematic Review and Bayesian Network Meta-Analysis<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To compare the efficacy and safety of abaloparatide (ABA), denosumab (DEN), teriparatide (TER), oral bisphosphonates (OBP), and intravenous bisphosphonates (IBP) in the treatment of male osteoporosis through a network meta-analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Summary of Background Data<\/jats:title><jats:p>Currently, a variety of medications are available for the treatment of male osteoporosis, including abaloparatide, denosumab, teriparatide, and bisphosphonates. These medications are widely applied in male osteoporosis, and existing randomized controlled trials (RCTs) provide strong evidence of their efficacy. However, there is a lack of sufficient systematic comparative studies to guide the choice between these treatments, particularly for specific male osteoporosis populations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This systematic review and network meta-analysis (NMA) were conducted strictly in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines and the relevant standards recommended by the Cochrane Collaboration. We performed pairwise meta-analysis using Stata 18.0 software to assess the magnitude of effect sizes and the consistency of findings across studies. For network meta-analysis (NMA), we used R version 4.3.1 along with the gemtc and BUGSnet packages to handle complex multi-treatment comparisons. Using these methods, we were able to comprehensively assess the relative efficacy and safety of different treatment options. All statistical analyses were conducted using Review Manager software (version 5.4), a widely used tool in medical research for meta-analysis, forest plot generation, and bias risk assessment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, clinical decisions should carefully balance drug efficacy and safety. Although TER performs best in reducing the occurrence of all adverse events, its efficacy in some BMD targets (such as total hip BMD) is relatively lower. In comparison, while OBP has a clear advantage in reducing severe adverse events, its efficacy in some BMD improvements (such as femoral neck BMD) is slightly less. Therefore, clinicians should consider the specific needs of the patient, the treatment goals, and the safety profile of the drug when selecting a medication, particularly for long-term use.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The results indicate that abaloparatide and teriparatide are significantly superior to other drugs in improving lumbar spine and femoral neck BMD, while oral bisphosphonates is the most effective in improving total hip BMD. In terms of safety, teriparatide demonstrates the best performance in all adverse events, and oral bisphosphonates shows a clear advantage in reducing severe adverse events. Future treatment decisions should balance efficacy and safety, with clinical treatment tailored to the individual needs of the patient, including the site of bone loss and sensitivity to adverse events. Future research should explore combination therapies or multi-target strategies to optimize both efficacy and safety.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2025.1558560","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T04:12:13Z","timestamp":1744776733000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of abaloparatide, denosumab, teriparatide, oral bisphosphonates, and intravenous bisphosphonates in the treatment of male osteoporosis: a systematic review and Bayesian network meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Liangshi","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bomei","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cong","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2016.1124856","article-title":"Management of severe osteoporosis","volume":"17","author":"Miller","year":"2016","journal-title":"Expert Opin pharmacotherapy"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.11622\/smedj.2021036","article-title":"Menopausal osteoporosis: screening, prevention and treatment","volume":"62","author":"Yong","year":"2021","journal-title":"Singapore Med J"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.20945\/2359-3997000000563","article-title":"Male osteoporosis","volume":"66","author":"Bandeira","year":"2022","journal-title":"Arch Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2269","article-title":"The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine","volume":"29","author":"Wright","year":"2014","journal-title":"J Bone mineral research: Off J Am Soc Bone Mineral Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s43465-023-01027-w","article-title":"Male osteoporosis and frailty","volume":"57","author":"Barik","year":"2023","journal-title":"Indian J Orthopaedics"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22042105","article-title":"Osteoporosis in men: A review of an underestimated bone condition","volume":"22","author":"Rinonapoli","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.061113","article-title":"Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025","volume":"22","author":"Burge","year":"2007","journal-title":"J Bone mineral research: Off J Am Soc Bone Mineral Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/s2255-4971(15)30425-0","article-title":"Male osteoporosis","volume":"45","author":"Oliveira","year":"2010","journal-title":"Rev Bras ortopedia"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2022.101766","article-title":"Male osteoporosis-what are the causes, diagnostic challenges, and management","volume":"36","author":"Bj\u00f6rnsdottir","year":"2022","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2018.1428559","article-title":"New and developing pharmacotherapy for osteoporosis in men","volume":"19","author":"Gennari","year":"2018","journal-title":"Expert Opin Pharmacotherapy"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2147\/cia.S44057","article-title":"Treatment of primary osteoporosis in men","volume":"10","author":"Giusti","year":"2015","journal-title":"Clin Interventions Aging"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s40520-022-02272-z","article-title":"Novel formulations of oral bisphosphonates in the treatment of osteoporosis","volume":"34","author":"Fuggle","year":"2022","journal-title":"Aging Clin Exp Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1634\/theoncologist.9-90004-28","article-title":"Safety of intravenous and oral bisphosphonates and compliance with dosing regimens","author":"Conte","year":"2004","journal-title":"oncologist"},{"key":"B14","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1186\/s12891-023-06865-1","article-title":"Clinicians\u2019\u2002views of prescribing oral and intravenous bisphosphonates for osteoporosis: A qualitative study","volume":"24","author":"Bishop","year":"2023","journal-title":"BMC Musculoskeletal Disord"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174409","article-title":"Abaloparatide: A review of preclinical and clinical studies","volume":"909","author":"Brent","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab850","article-title":"Denosumab after teriparatide in premenopausal women with idiopathic osteoporosis","volume":"107","author":"Shane","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: A randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"Jama"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp070171","article-title":"Teriparatide in the treatment of osteoporosis","volume":"65","author":"Stroup","year":"2008","journal-title":"Am J health-system pharmacy: AJHP: Off J Am Soc Health-System Pharmacists"},{"key":"B19","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s41687-024-00727-7","article-title":"Guideline for reporting systematic reviews of outcome measurement instruments (Omis): prisma-cosmin for omis 2024","volume":"8","author":"Elsman","year":"2024","journal-title":"J patient-reported outcomes"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1055\/a-1984-0466","article-title":"Correlation between forearm bone mineral density measured by dual energy X-ray absorptiometry and hounsfield units value measured by ct in lumbar spine","volume":"162","author":"Pu","year":"2024","journal-title":"Z fur Orthopadie und Unfallchirurgie"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s43390-023-00646-5","article-title":"Discrepancy between dxa and ct-based assessment of spine bone mineral density","volume":"11","author":"Davidson","year":"2023","journal-title":"Spine deformity"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3641","article-title":"Change in bone density and reduction in fracture risk: A meta-regression of published trials","volume":"34","author":"Bouxsein","year":"2019","journal-title":"J Bone mineral research: Off J Am Soc Bone Mineral Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1177\/08968608221146867","article-title":"Differences in prevalence of reduced and low bone mineral density between lumbar spine and femoral neck in peritoneal dialysis patients using dual-energy X-ray absorptiometry (Dxa)","volume":"43","author":"Davenport","year":"2023","journal-title":"Peritoneal Dialysis international: J Int Soc Peritoneal Dialysis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-020-00744-w","article-title":"Effects of different types of exercise on bone mineral density in postmenopausal women: A systematic review and meta-analysis","volume":"107","author":"Kemmler","year":"2020","journal-title":"Calcified Tissue Int"},{"key":"B25","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.crtox.2020.06.001","article-title":"Development of an adverse drug event network to predict drug toxicity","volume":"1","author":"Wu","year":"2020","journal-title":"Curr Res Toxicol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-069722","article-title":"Viscosupplementation for knee osteoarthritis: systematic review and meta-analysis","volume":"378","author":"Pereira","year":"2022","journal-title":"BMJ (Clinical Res ed)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1446","article-title":"Efficacy, acceptability, and safety of muscle relaxants for adults with non-specific low back pain: systematic review and meta-analysis","volume":"374","author":"Cashin","year":"2021","journal-title":"BMJ (Clinical Res ed)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/ccm.0000000000005343","article-title":"21st century evidence: randomized controlled trials versus systematic reviews and meta-analyses","volume":"49","author":"Agarwal","year":"2021","journal-title":"Crit Care Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.15.1987","article-title":"The consort statement: revised recommendations for improving the quality of reports of parallel-group randomized trials","volume":"285","author":"Moher","year":"2001","journal-title":"Jama"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.Ed000145","article-title":"Prospective meta-analyses and cochrane\u2019s role in embracing next-generation methodologies","volume":"10","author":"Seidler","year":"2020","journal-title":"Cochrane Database systematic Rev"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000013052","article-title":"Assessing the methodological and reporting quality of network meta-analyses in chinese medicine","volume":"97","author":"Yang","year":"2018","journal-title":"Medicine"},{"key":"B32","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12874-019-0829-2","article-title":"Bugsnet: an R package to facilitate the conduct and reporting of bayesian network meta-analyses","volume":"19","author":"B\u00e9liveau","year":"2019","journal-title":"BMC Med Res Method"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.bja.2022.08.042","article-title":"Epidemiological, methodological, and statistical characteristics of network meta-analysis in anaesthesia: A systematic review","volume":"130","author":"Sehmbi","year":"2023","journal-title":"Br J anaesthesia"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1054","article-title":"Automating network meta-analysis","volume":"3","author":"van Valkenhoef","year":"2012","journal-title":"Res synthesis Methods"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-005-0004-4","article-title":"Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study","volume":"26","author":"Ringe","year":"2006","journal-title":"Rheumatol Int"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-008-0689-2","article-title":"Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study","volume":"29","author":"Ringe","year":"2009","journal-title":"Rheumatol Int"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2011.10.024","article-title":"Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate","volume":"50","author":"Sambrook","year":"2012","journal-title":"Bone"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1870","article-title":"Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the eurogiops trial","volume":"28","author":"Gl\u00fcer","year":"2013","journal-title":"J Bone mineral research: Off J Am Soc Bone Mineral Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2000.15.6.1006","article-title":"Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: A randomized trial","volume":"15","author":"Reid","year":"2000","journal-title":"Eur Corticosteroid-Induced Osteoporosis Treat Study. J Bone mineral research: Off J Am Soc Bone Mineral Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s002230001146","article-title":"Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy","volume":"67","author":"Wallach","year":"2000","journal-title":"Calcified Tissue Int"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000063820.94994.95","article-title":"Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer","volume":"169","author":"Smith","year":"2003","journal-title":"J Urol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet (London England)"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/art.40874","article-title":"Denosumab versus risedronate in glucocorticoid-induced osteoporosis: final results of a twenty-four-month randomized, double-blind, double-dummy trial","volume":"71","author":"Saag","year":"2019","journal-title":"Arthritis Rheumatol (Hoboken NJ)"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-4175","article-title":"Clinical trials express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (Direct)","volume":"99","author":"Nakamura","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac486","article-title":"Abaloparatide increases lumbar spine and hip bmd in Japanese patients with osteoporosis: the phase 3 active-J study","volume":"107","author":"Matsumoto","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1056\/nejm200008313430902","article-title":"Alendronate for the treatment of osteoporosis in men","volume":"343","author":"Orwoll","year":"2000","journal-title":"New Engl J Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-002-1085-7","article-title":"Alendronate treatment in men with primary osteoporosis: A three-year longitudinal study","volume":"73","author":"Gonnelli","year":"2003","journal-title":"Calcified Tissue Int"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-003-0388-y","article-title":"Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study","volume":"24","author":"Ringe","year":"2004","journal-title":"Rheumatol Int"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-012-9819-4","article-title":"Combination therapy with risedronate and teriparatide in male osteoporosis","volume":"44","author":"Walker","year":"2013","journal-title":"Endocrine"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.4314\/tjpr.v20i10.26","article-title":"Comparative efficacy and safety of alendronate and teriparatide in bone loss reduction and prevention of vertebral fracture in osteoporotic chinese patients","volume":"20","author":"Qi","year":"2021","journal-title":"Trop J Pharm Res"},{"key":"B51","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1359\/jbmr.2003.18.1.9","article-title":"The effect of teriparatide [Human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis","volume":"18","author":"Orwoll","year":"2003","journal-title":"J Bone mineral research: Off J Am Soc Bone Mineral Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-009-0136-9","article-title":"The effects of weekly alendronate therapy in Taiwanese males with osteoporosis","volume":"28","author":"Hwang","year":"2010","journal-title":"J Bone mineral Metab"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.119","article-title":"Efficacy and safety of a once-yearly I.V. Infusion of zoledronic acid 5\u2009Mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: A randomized, multicenter, double-blind, active-controlled study","volume":"25","author":"Orwoll","year":"2010","journal-title":"J Bone Mineral Research: Off J Am Soc Bone Mineral Res"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4719","article-title":"The efficacy and safety of abaloparatide-sc in men with osteoporosis: A randomized clinical trial","volume":"37","author":"Czerwinski","year":"2022","journal-title":"J Bone mineral research: Off J Am Soc Bone Mineral Res"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2009.12.034","article-title":"Efficacy and safety of monthly ibandronate in men with low bone density","volume":"46","author":"Orwoll","year":"2010","journal-title":"Bone"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1204061","article-title":"Fracture risk and zoledronic acid therapy in men with osteoporosis","volume":"367","author":"Boonen","year":"2012","journal-title":"New Engl J Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.081214","article-title":"Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study","volume":"24","author":"Boonen","year":"2009","journal-title":"J Bone mineral research: Off J Am Soc Bone Mineral Res"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2011.03666.x","article-title":"Once-yearly zoledronic acid in older men compared with women with recent hip fracture","volume":"59","author":"Boonen","year":"2011","journal-title":"J Am Geriatrics Soc"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-1569","article-title":"A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density","volume":"97","author":"Orwoll","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-004-1713-3","article-title":"Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy","volume":"16","author":"Kaufman","year":"2005","journal-title":"Osteoporosis international: J established as result cooperation between Eur Foundation Osteoporosis Natl Osteoporosis Foundation USA"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200424060-00003","article-title":"Weekly oral alendronic acid in male osteoporosis","volume":"24","author":"Miller","year":"2004","journal-title":"Clin Drug Invest"},{"key":"B62","doi-asserted-by":"publisher","first-page":"Cd002010","DOI":"10.1002\/14651858.CD002010.pub5","article-title":"Bisphosphonates for osteoporosis in people with cystic fibrosis","volume":"1","author":"Jeffery","year":"2023","journal-title":"Cochrane Database Systematic Rev"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1558560\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T04:12:14Z","timestamp":1744776734000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1558560\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":62,"alternative-id":["10.3389\/fendo.2025.1558560"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1558560","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,16]]},"article-number":"1558560"}}